Filing Flows › Core Laboratories (CLB) › Q3 2026 › vs Q3 2025
Core Laboratories (CLB) Q3 2026 vs Q3 2025 (year over year)
Core Laboratories's revenue fell $2.4M (-2%) from $135M in Q3 2025 to $132M in Q3 2026. The biggest changes: Service −$5.1M (-5%); Product +$2.7M (+8%). Operating margin 9.1% against 15.6% (-6.4 pts).
Core Laboratories, Q3 2026: revenue $132M (-2% year over year), operating margin 9.1%, net earnings $5.4M, operating cash flow $5.0M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Operating margin | 9.1% | 15.6% | -6.4 pts |
| Net margin | 4.1% | 10.6% | -6.5 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Service | $96.0M | $101M | −$5.1M | -5% |
| Product | $36.1M | $33.4M | $2.7M | +8% |
| Revenue | $132M | $135M | −$2.4M | -2% |
| Operating profit | $12.1M | $20.9M | −$8.9M | -42% |
| Costs & expenses | $120M | $114M | $6.4M | +6% |
| Pre-tax earnings | $9.3M | $18.3M | −$9.0M | -49% |
| Other expense, net | $2.8M | $2.6M | $136K | +5% |
| Net earnings | $5.4M | $14.2M | −$8.8M | -62% |
| Minority interests | $19K | $285K | −$266K | -93% |
| Income tax | $3.8M | $3.8M | $62K | +2% |
| Operating cash sources | $10.5M | $19.2M | −$8.7M | -45% |
| Depreciation & amortization | $3.7M | $3.6M | $130K | +4% |
| Share-based compensation | $1.3M | $1.3M | −$42K | -3% |
| Working capital & other | $5.5M | $10.7M | −$5.2M | -49% |
| Operating cash flow | $5.0M | $8.5M | −$3.5M | -42% |
Questions
How much did Core Laboratories's revenue grow year over year in Q3 2026?
Core Laboratories's revenue fell $2.4M (-2%) from $135M in Q3 2025 to $132M in Q3 2026.
What drove Core Laboratories's revenue change in Q3 2026?
Service −$5.1M (-5%); Product +$2.7M (+8%).